Interferon Beta-1b
Treatment of relapsing-remitting multiple sclerosis in ambulatory patients diagnosed using McDonald criteria, including those with a single clinical attack and MRI evidence of dissemination in space and time.
Access path
- Mar 2007Not recommended
uncertain clinical benefit (delay in MS diagnosis does not clearly translate to slower disability progression)…
- Mar 2007Not recommended
uncertain clinical benefit (delay in MS diagnosis not clearly translating to slower disability progression), uncertain…
Cost-effectiveness
Trial-based cost per extra patient avoiding CDMS diagnosis at 2 years; modelled economic evaluations were not adequately informative.
The PBAC concluded that the submission's claim that it is cost-effective to initiate treatment with INFN beta-1b upon diagnosis of MS by the McDonald criteria was not adequately supported by the evidence presented. PBAC · 2007
Decision context
PopulationAmbulatory patients with one or more documented attacks of neurological dysfunction suggestive of multiple sclerosis, with MRI evidence of dissemination in space and time according to McDonald criteria, without evidence of alternative diagnoses.
Why it was knocked back
- uncertain clinical benefit (delay in MS diagnosis not clearly translating to slower disability progression), uncertain cost-effectiveness, concerns about specificity of McDonald criteria in differentiating MS from other neurological conditions, economic uncertainties arising from clinical uncertainties
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2007 | Not recommended | placebo | $105k–200k | RCT |
| Mar 2007 | Not recommended | placebo | $105k–200k | RCT |